Athenecia Faggins of Minaris Advanced Therapies discusses raw material qualification, supplier management, testing, and risk control for advanced therapy manufacturing.
|Articles|May 3, 2018
WuXi Biologics to Invest $389 Million in New Biomanufacturing Facility
Author(s)BioPharm International Editors
The company will invest EUR 325 million (US$389 million) in a new biomanufacturing facility in Ireland using single-use bioreactors.
Advertisement
On April 30, 2018, WuXi Biologics, part of WuXi AppTech, announced plans to invest EUR 325 million (US$389 million) in a new biomanufacturing facility in Mullagharlin, Dundalk, County Louth, Ireland.
According to the company, the new facility will use multiple single-use bioreactors for commercial biomanufacturing and is designed to be able to run continuous bioprocessing. A total of 48,000 L fed-batch and 6,000 L perfusion bioreactor capacity will also be installed.
The site will be on a 26-hectare campus and is the company’s first site outside of China. The investment is expected to create over 400 skilled jobs over a five-year span, as well as add approximately 700 construction jobs.
The project is supported by the Irish Government through IDA Ireland, an economic development body for Ireland.
Source:
Advertisement
Related to this article
Panelists from FDA, Genentech, and Minaris discussed raw material risk, supplier oversight, and at-risk release strategies for advanced therapies at the PDA/FDA Joint Regulatory Conference.
Sanofi's Dr Jack Prior detailed a data maturity framework for biologics manufacturing, while FDA and Gilead panelists debated risk-based AI validation.
FDA's consumer safety officer, Jason Chancey, detailed real inspection findings, such as taped gaskets and delayed retesting, behind sterile facility deficiencies.
Insilico's Longevity Vaccines use circular mRNA to arm T cells against aging's earliest culprit cells, starting with immune rejuvenation.
Tambotatug pelitecan (Tam-Peli), a B7-H3-targeted antibody-drug conjugate, is the second of at least three B7-H3-targeted ADCs to post positive late-stage data in relapsed small-cell lung cancer this year.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Phio's PH-762 posted a 70% response rate in skin cancer, supporting its FDA briefing package for a planned phase 2b trial.
Advertisement
Advertisement